8 research outputs found
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)
Objectives. The specific objective of the REDUCE trial was to evaluate the effect of low molecular weight heparin on the incidence and occurrence of restenosis in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Background. Unfractionated heparin and its low molecular weight fragments possess antiproliferative effects and have been shown to reduce neointimal smooth muscle cell migration and proliferation in response to vascular injury in experimental studies. Methods. The REDUCE trial is an international prospective, randomized, double-blind, multicenter study. Twenty-six centers in Europe and Canada enrolled 625 patients with single-lesion coronary artery obstructions suitable for PTCA. Three hundred six patients received reviparin as a 7,000-U bolus before PTCA, followed by 10,500 U as an infusion over 24 h and then twice-daily 3,500-U subcutaneous application for 28 days. The 306 patients in the control group received a bolus of 10,000 U o
Heavy quarkonium: progress, puzzles, and opportunities
A golden age for heavy quarkonium physics dawned a decade ago, initiated by
the confluence of exciting advances in quantum chromodynamics (QCD) and an
explosion of related experimental activity. The early years of this period were
chronicled in the Quarkonium Working Group (QWG) CERN Yellow Report (YR) in
2004, which presented a comprehensive review of the status of the field at that
time and provided specific recommendations for further progress. However, the
broad spectrum of subsequent breakthroughs, surprises, and continuing puzzles
could only be partially anticipated. Since the release of the YR, the BESII
program concluded only to give birth to BESIII; the -factories and CLEO-c
flourished; quarkonium production and polarization measurements at HERA and the
Tevatron matured; and heavy-ion collisions at RHIC have opened a window on the
deconfinement regime. All these experiments leave legacies of quality,
precision, and unsolved mysteries for quarkonium physics, and therefore beg for
continuing investigations. The plethora of newly-found quarkonium-like states
unleashed a flood of theoretical investigations into new forms of matter such
as quark-gluon hybrids, mesonic molecules, and tetraquarks. Measurements of the
spectroscopy, decays, production, and in-medium behavior of c\bar{c}, b\bar{b},
and b\bar{c} bound states have been shown to validate some theoretical
approaches to QCD and highlight lack of quantitative success for others. The
intriguing details of quarkonium suppression in heavy-ion collisions that have
emerged from RHIC have elevated the importance of separating hot- and
cold-nuclear-matter effects in quark-gluon plasma studies. This review
systematically addresses all these matters and concludes by prioritizing
directions for ongoing and future efforts.Comment: 182 pages, 112 figures. Editors: N. Brambilla, S. Eidelman, B. K.
Heltsley, R. Vogt. Section Coordinators: G. T. Bodwin, E. Eichten, A. D.
Frawley, A. B. Meyer, R. E. Mitchell, V. Papadimitriou, P. Petreczky, A. A.
Petrov, P. Robbe, A. Vair
Smooth muscle cell proliferation and restenosis after stand alone coronary excimer laser angioplasty
Percutaneous Coronary Excimer Laser Angioplasty in Patients With Stable and Unstable Angina Pectoris Acute Results and Incidence of Restenosis During 6-Month Follow-up
A clinical study was conducted to evaluate the efficacy and safety of percutaneous coronary excimer laser angioplasty in 60 patients with coronary artery disease. Forty-nine patients had stable exertional angina, and 11 patients had unstable angina despite medical therapy. A novel 1.4-mm diameter catheter with 20 quartz fibers of 100-gm diameter each arranged concentrically around a central lumen suitable for a 0.014-in. flexible guide wire was coupled to an excimer laser. A commercial excimer laser emitting energy at a wavelength of 308 nm with a pulse duration of 60 nsec was used. The laser was operated at 20 Hz. Mean energy transmission was 30±+5 mJ/mm2. In five of the 60 patients, laser angioplasty was not attempted. In 23 patients with laser ablation alone, percent stenosis decreased from 76±14% before to 27±17% after ablation and was 34±15% at the early follow-up angiogram. In 32 patients, additional balloon angioplasty was performed because of vessel closure after laser ablation in 11 and an insufficient qualitative result in 21 patients. Of the 11 patients with unstable angina, one patient died due to vessel closure 3 hours after intervention, and two patients developed a myocardial infarction. In 22 of 47 patients with late follow-up angiography, restenosis within the 6-month follow-up period occurred. Rate of restenosis was higher in patients treated with laser ablation and balloon angioplasty (16 of 28) than in patients treated with laser ablation alone (six of 19). These results suggest that coronary excimer laser angioplasty for ablation of obstructive lesions is feasible and safe in patients with stable angina. However, development of new catheter systems is necessary for an improved success rate. (Circulation 1990;81:1849-1859 In 1977, Andreas Gruntzig introduced the technique of transluminal balloon dilatation of coronary artery stenoses for treatment of atherosclerotic obstructions.' Conventional balloon angioplasty has shown impressive clinical results but is limited by a restenosis rate that approaches 30-40%.2,3 Laser technology was suggested as an alternative approach for treatment of coronary artery disease. However, the technique of laser recanalization or laser angioplasty so far has been limited by a 20-30% incidence of vessel perforation in experimental4'5 and clinical6'7 studies. Among the considerable variety of lasers, the excimer laser has been suggested to represent a Fro
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
BACKGROUND: Many patients with acute coronary syndromes are offered percutaneous coronary intervention. However, the appropriate indications for, and optimal timing of, such procedures are uncertain. We analysed timing of intervention and associated events (death and myocardial infarction) in the PURSUIT trial in which 9461 patients received a platelet glycoprotein IIb/IIIa inhibitor, eptifibatide, or placebo for 72 h. Other treatment was left to the investigators. 2430 patients underwent percutaneous coronary intervention within 30 days. Four groups were distinguished, who underwent percutaneous coronary intervention on day 1; on days 2 or 3; at 4 to 7 days; or between 8 until 30 days, for eptifibatide- and placebo-treated patients. RESULTS: The four groups treated with placebo demonstrated total 30-
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
BACKGROUND: A proportion of patients who present with suspected acute
coronary syndrome (ACS) are found to have insignificant coronary artery
disease (CAD) during coronary angiography, but these patients have not
been well characterized. METHODS AND RESULTS: Of the 5767 patients with
non-ST-segment elevation ACS who were enrolled in the Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using
Integrilin (Eptifibatide) Therapy (PURSUIT) trial and who underwent
in-hospital angiography, 88% had significant CAD (any stenosis >50%), 6%
had mild CAD (any stenosis >0% to </=50%), and 6% had no CAD (no stenosis
identified). The frequency of death or nonfatal myocardial infarction at
30 days was reduced with eptifibatide treatment in patients with
significant CAD (18.3% versus 15.6% for placebo, P=0.006) but not in those
with mild CAD (6.6% versus 5.4%, P=0.62) and with no CAD (3.0% versus 1.
2%, P=0.28). We identified independent baseline predictors of
insignificant CAD (mild or no CAD) and used them to develop a simple
predictive nomogram of the probability of insignificant CAD for use at
hospital presentation. This nomogram was validated in a separate
population of patients with non-ST-segment elevation ACS. CONCLUSIONS:
Patients with suspected ACS found to have insignificant CAD have a low
risk of adverse outcomes, do not appear to benefit from treatment with
eptifibatide, and can be predicted with a simple nomogram drawn from
baseline characteristics. Because patients with significant CAD appear to
have an enhanced benefit from eptifibatide treatment, the predictive
nomogram developed can be used to determine indications for glycoprotein
IIb/IIIa blockade